Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Change in Inventory (2016 - 2025)

Historic Change in Inventory for Harvard Bioscience (HBIO) over the last 17 years, with Q3 2025 value amounting to -$637000.0.

  • Harvard Bioscience's Change in Inventory fell 19535.93% to -$637000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.6 million, marking a year-over-year decrease of 53530.52%. This contributed to the annual value of $64000.0 for FY2024, which is 10419.95% up from last year.
  • According to the latest figures from Q3 2025, Harvard Bioscience's Change in Inventory is -$637000.0, which was down 19535.93% from -$977000.0 recorded in Q2 2025.
  • In the past 5 years, Harvard Bioscience's Change in Inventory registered a high of $1.9 million during Q2 2021, and its lowest value of -$2.4 million during Q4 2024.
  • Moreover, its 5-year median value for Change in Inventory was $292000.0 (2023), whereas its average is $98157.9.
  • In the last 5 years, Harvard Bioscience's Change in Inventory soared by 503333.33% in 2021 and then plummeted by 25361.37% in 2022.
  • Harvard Bioscience's Change in Inventory (Quarter) stood at $1.8 million in 2021, then plummeted by 132.05% to -$581000.0 in 2022, then tumbled by 132.53% to -$1.4 million in 2023, then crashed by 74.09% to -$2.4 million in 2024, then skyrocketed by 72.92% to -$637000.0 in 2025.
  • Its last three reported values are -$637000.0 in Q3 2025, -$977000.0 for Q2 2025, and -$670000.0 during Q1 2025.